
Biomedical engineer Leyla Soleymani’s team was responsible for the hardware, including the chip that reads the sample.
Researchers at McMaster and Brock universities have created the prototype for a hand-held device to measure a biomarker for cancer, paving the way for home-based cancer monitoring and to improve access to diagnostic testing.
The device works much like the monitors that people with diabetes use to test their blood-sugar levels and could be used in a medical clinic or at home, all without lab work, greatly simplifying the process for testing blood for cancer’s signature.
A user would mix a droplet of blood in a vial of reactive liquid, then place the mixture onto a strip and insert it into a reader. In minutes, the device would measure an antigen that indicates the degree to which cancer is present.
The prototype has been designed to monitor prostate specific antigen (PSA) and the technology can readily be adapted to measure other markers, depending on the form of cancer or other chronic disease.
The ability to collect such information at home would make the daily lives of patients much easier while also generating accurate, shareable, up-to-the-minute results to guide their doctors in shaping care and treatment – all at a lower cost to the health-care system.
The device would also allow patients to continue to monitor their health after treatment.
The prototype was created by a research collaboration led by McMaster’s Leyla Soleymani, a biomedical engineer and Canada Research Chair in Miniaturized Biomedical Devices, and Brock’s Feng Li, an associate professor of chemistry who leads a bioanalytical chemistry lab.
Soleymani’s team (also including Sarah Traynor and Richa Pandey) was responsible for the hardware, including the chip that reads the sample, while Li’s team (also including Guan Wang) created the technology that analyzes the sample.
“This is another step toward truly personalized medicine,” Soleymani says. “We’re getting away from centralized, lab-based equipment for this kind of testing.
“This would make monitoring much more accessible and cut down on the number of times patients need to leave home to provide blood samples.”
Once commercialized, this device will be a paradigm shift for cancer diagnosis and prognosis, Li says.
“Since this device is a lot more accessible and user-friendly than conventional technologies, patients will be more willing to use it, which can improve clinical outcomes and save lives.”
The researchers’ proof-of-concept work is described in an article published in the journal Angewandte Chemie. The invention will need to be tested more broadly before earning the regulatory approvals that would permit commercial manufacturing
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cancer biomarkers
- NIH and PhysIQ Complete Initial Phase of COVID-19 Digital Biomarker Development; Pen Contract for Phase IIon January 19, 2021 at 10:01 pm
The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), exercised their option to enter Phase II of ...
- Second Genome To Present Biomarker Data in Oncology at Keystone Symposiumon January 19, 2021 at 4:28 am
Second Genome, a leader in microbiome science, will present data today demonstrating the identification of a microbiome-based composite biomarker which can be used to predict response to immune ...
- AstraZeneca, Daiichi's breast cancer drug gets broader U.S. approvalon January 18, 2021 at 5:14 am
AstraZeneca and Daiichi Sankyo's breast cancer drug has been approved as a treatment for a certain type of advanced gastric cancer in the United States, the British drugmaker said on Monday.
- COBRA Study to Test ctDNA as Biomarker for Adjuvant Chemotherapy Benefit in Colon Canceron January 17, 2021 at 6:02 am
Click here to read more of Cancer Therapy Advisor‘s conference coverage. The NRG-GI005 (COBRA) study is the first phase 3 trial to test circulating tumor DNA (ctDNA) as a predictive biomarker for ...
- New tests may help improve the selection of men considering prostate cancer surveillanceon January 17, 2021 at 5:13 am
Sylvester Comprehensive Cancer Center researchers are looking at ways to combine imaging and biomarkers to predict prostate cancer progression more accurately.
Go deeper with Google Headlines on:
Cancer biomarkers
Go deeper with Bing News on:
Cancer biomarker detector
- Researchers develop a new approach to detect pancreatic canceron January 20, 2021 at 12:14 am
Researchers develop a new approach to ... A protein found commonly in human blood might help with the detection of hard-to-diagnose pancreatic tumours. Researchers at Martin Luther University ...
- Caris Life Sciences Accurately Identifies 21 Cancer Types Using Artificial Intelligence Derived Molecular Signatureson January 19, 2021 at 10:24 pm
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, today announced positive results from a study using ...
- Liquid Biopsy Predicts Colon Cancer Relapse Months Before CTon January 17, 2021 at 2:05 pm
Detection of circulating tumor DNA (ctDNA) after surgery for colorectal cancer (CRC) identified patients with a high risk of relapse, which could be modified by adjuvant chemotherapy in some cases, ...
- COBRA Study to Test ctDNA as Biomarker for Adjuvant Chemotherapy Benefit in Colon Canceron January 17, 2021 at 6:02 am
Van K. Morris, MD, the principal investigator of the study (ClinicalTrials.gov identifier: NCT04068103), noted that there are currently no validated predictive biomarkers for stage II resected colon ...
- New tests may help improve the selection of men considering prostate cancer surveillanceon January 17, 2021 at 5:13 am
Sylvester Comprehensive Cancer Center researchers are looking at ways to combine imaging and biomarkers to predict prostate cancer progression more accurately.